Recursion Pharmaceuticals, Inc ( (RXRX) ) has released its Q3 earnings. Here is a breakdown of the information Recursion Pharmaceuticals, Inc presented to its investors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Recursion Pharmaceuticals, Inc., a clinical stage TechBio company, is focused on decoding biology to improve lives through its AI-enabled platform, Recursion OS, which combines large datasets with supercomputing capabilities. In its third quarter of 2025, Recursion achieved a significant milestone by receiving a $30 million payment from Roche and Genentech for a whole-genome map of microglial immune cells, contributing to over $500 million in milestone and upfront payments across its partnerships. The company reported a cash position of approximately $785 million, providing a financial runway through the end of 2027 without additional financing.
Key financial metrics for the quarter included a total revenue of $5.2 million, a decrease from the previous year due to milestone timing, and a net loss of $162.3 million, which increased from the prior year due to higher research and development expenses. These expenses were driven by the acquisition of full rights to REC-102 and the business combination with Exscientia. Recursion’s internal pipeline saw progress with REC-617 and REC-7735, while partnered programs with Roche, Genentech, and Sanofi continued to advance.
The company highlighted the power of its Recursion OS in driving pipeline momentum, with REC-617 showing promising results in its ELUCIDATE trial and REC-7735 advancing as a development candidate. Partnered discovery efforts with Roche and Genentech resulted in significant milestone payments, underscoring the strength of Recursion’s collaboration strategy. The company’s platform, Recursion OS 2.0, continues to integrate AI for innovative drug discovery and development.
Looking ahead, Recursion is poised to leverage its strong cash position and strategic partnerships to advance its pipeline and platform. The company remains focused on delivering transformative medicines and achieving further milestones, with expectations of over $100 million in milestone payments by the end of 2026. Recursion’s management expresses confidence in the potential of its AI-enabled platform to drive future growth and innovation in the biotechnology sector.